Alkem Laboratories Ltd - 539523 - Closure of Trading Window
This is to inform you that in terms of Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from 30th December, 2018 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and nine months ended 31st December, 2018 are communicated to the Stock Exchanges. Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
In furtherance to our intimation dated 2nd November, 2018, this is to inform you that pursuant to the provisions of Section 110 and other applicable provisions, if any, of the Companies Act, 2013 read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014, the Company is in the process of conducting postal ballot (including voting by electronic means) for seeking approval of members of the Company for businesses as specified...
USFDA closes inspection of Alkem's St Louis manufacturing facility
Alkem's St Louis facility was inspected by the USFDA from 12 March 2018 to 16 March 2018 Announcement under Regulation 30 (LODR)-Press Release / Media Release
In furtherance to the intimation captioned "US FDA Inspection at Alkem's manufacturing facility located at St. Louis, USA" dated 28th March, 2018, this is to inform you that US FDA has issued an Establishment Inspection Report (EIR) for the Company's manufacturing facility located at St. Louis, USA which was inspected from 12th March, 2018 to 16th March, 2018.... Intimation Regarding A Request Received From A Member Of The Promoter Group For Reclassification From The Promoter/Promoter Group Of Alkem Laboratories Limited.
This is to inform you that, the Board of Directors of the Company ('Board') has received a request from Mr. Nawal Kishore Singh, son of Mr. Samprada Singh and brother of Mr. Satish Kumar Singh and Mr. Balmiki Prasad Singh, Promoters of the Company, holding 43,11,060 equity shares of the Company (3.61% of total paid up equity share capital) for reclassifying his shareholding in the Company from the 'Promoter Group' category to the 'Public' shareholding... Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to inform you that US FDA had conducted an inspection at the Company's Bioequivalence facility located at Taloja, Maharashtra from 8th November, 2018 to 14th November, 2018. At the end of the inspection, no Form 483 was issued. Kindly take note of the same. Alkem Lab Q2 net dips 20.64% to 254.5 cr
Alkem Laboratories on Friday said its net profit (after minority interest) fell by 20.64 per cent year-on-year to 254.5 crore in the quarter ended S Cut-Off Date For Postal Ballot
This is to inform you that pursuant to the provisions of Section 110 and other applicable provisions, if any, of the Companies Act, 2013, the Board of Directors at its meeting held today i.e. 2nd November, 2018 have decided to seek approval of the shareholders by way of postal ballot (including voting by electronic means) for: 1.Continuance of office of Mr. Samprada Singh as Chairman Emeritus and Non-Executive Director of Company and Mr.... Closure of Trading Window
We refer to our earlier communication dated 27th September, 2018 regarding closure of trading window (for the purpose of financial results for the quarter ended 30th September, 2018) starting from 29th September, 2018 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and half year ended 30th September, 2018 are communicated to the Stock Exchanges.... Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30Th September, 2018.
In continuation of our letter dated 23rd October, 2018 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we are enclosing the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2018, duly approved by the Board of Directors of the Company, at its meeting...